Abstract:Fabrizio Martora, Teresa Battista, &ast Luca Potestio, &ast Antonio Portarapillo, Nello Tommasino, Matteo Megna Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy &astThese authors contributed equally to this work Correspondence: Fabrizio Martora, Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, Napoli, 80131, Italy, Tel +39 081 7462457, Fax +39 081 7462442, Email Managing HS has long posed a significant challenge for dermatologists. Adalimumab stands as the sole biologic drug sanctioned for HS, receiving approval in 2015 as an anti-tumor necrosis factor (TNF)-α drug. Real-life evidence over the years has debated its efficacy, suggesting a success rate hovering around 70%. However, the variability in existing treatments and the chronic-recurrent nature of the condition make its treatment and management exceedingly challenging. Hence, identifying new therapeutic targets for HS in the future becomes imperative. Recently, on October 31, 2023, the FDA approved secukinumab for moderate-severe HS, marking a significant development. There has been substantial discourse on the potential of anti-interleukin-23 drugs as new therapeutic avenues for treating HS in recent years. Here, we report a case of 17-year-old man successfully treated with Guselkumab. The results were confirmed at week 52. Keywords: hidradenitis suppurativa, anti-IL23, guselkumab, adalimumab, secukinumab Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and disabling skin condition that affects hair follicles. It is characterized by painful lesions affecting areas of the body where apocrine glands are present. 1,2 While the precise underlying pathogenic mechanism of HS remains uncertain, initial follicular hyperkeratosis within the pilosebaceous-apocrine unit is considered the primum movens. Recent studies have provided new insights into the role of pro-inflammatory cytokines in HS pathogenesis, helping to address some existing gaps in our understanding of the development of this condition. 3,4 To date, the first FDA-approved biologic drug for HS is adalimumab, an anti-tumor necrosis factor (TNF)-α approved in 2015. Several real-life studies have highlighted a mean clinical success rate of approximately 70%. 5,6 However, primary or secondary lack of efficacy may occur. 7–10 Secukinumab, an anti-interleukin 17A drug approved for moderate to severe psoriasis and psoriatic arthritis (PsA), has shown promising results in clinical trials by improving signs and symptoms of HS with a good safety profile, maintaining a positive response for up to 52 weeks. 11 Even a few real-life data already align with these studies. 11 Recently, the European Commission (EC) approved secukinumab for use in adults with active moderate to severe HS, 12 while FDA approval was granted just a few months ago (October 31, 2023). Managing HS still remains challenging due to the variable outcomes of available treatments, and its chronic-recurrent nature; there is a huge need of new therapeutic targets for HS in order to take control of the disease in long-term. In this context, significant attention has been directed toward understanding the role of anti-IL-23 drugs in treating HS, thanks to the real-life studies and experiences recently published in literatures. Presently, there are three Phase 2 studies investigating these drugs alongside several case studies and case series, showcasing highly variable outcomes 12 Indeed, different drugs with diverse mechanism of action are being tested for HS (eg spesolimab, porvocitinib and bimekizumab). 13–15 Here, we report a case of 17-year-old man affected by HS since 3 years presenting nodules and fistulous routes in the axillary cavity, inguinal region, and on the buttocks (Hurley stage II, IHS4 16) (Figure 1A–C). His medical history was unremarkable except heart failure (NYHA1) related to surgery performed in childhood for a congenital atrial shunt. His family history was negative for inflammatory disease except for Crohn's disease (father). The patient had already been on several courses of antibiotics with rifampicin (600 mg) and clindamycin (600 mg) for up to 8 weeks or tetracyclines up to 8 weeks without receiving substantial benefit. Hence, we decided to start Guselkumab following the dosing for adult psoriasis, 100 mg at week 0 and week 4 followed by a maintenance dose every 8 weeks 16–18 avoiding adalimumab and secukinumab due to possible contraindications (heart failure and Crohn's disease familiarity, respectively). At week 16 HiSCR (Hidradenitis Suppurativa Clinical Response) was achieved (IHS4 6), lesions were reduced in bot -Abstract Truncated-

Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice

European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa

Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US

Hidradenitis suppurativa: new insights into disease mechanisms and an evolving treatment landscape

Characteristics and treatment pathways in pediatric and adult hidradenitis suppurativa: An examination using real world data

Belgian Patients of the European Registry for Hidradenitis Suppurativa (ERHS-Be): Data, Scores, and Phenotypes since 2015

Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa

P230 Clinical characteristics, risk factors and management of patients with inflammatory bowel disease and hidradenitis suppurativa: a nationwide multicenter study of the GETECCU ENEIDA registry

The most recent advances in understanding and managing hidradenitis suppurativa

Assessing the Role of Adalimumab in Treating Hidradenitis Suppurativa: Findings from a Retrospective Study at a Reference Center

Essentials of hidradenitis suppurativa: a comprehensive review of diagnostic and treatment perspectives

Hidradenitis suppurativa is associated with severe sexual impairment

Assessment of Familial Risk in Patients with Hidradenitis Suppurativa

Epidemiology and clinical correlates of hidradenitis suppurativa in primary care in Italy

Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report

New insights on hidradenitis suppurativa phenotypes and treatment response: An exploratory automated analysis of the SUNSHINE and SUNRISE trials

Sex-disaggregated population analysis in patients with hidradenitis suppurativa

Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study

Prevalence and Predictors of Inflammatory Arthritis in Hidradenitis Suppurativa

Epidemiology of Hidradenitis Suppurativa: Current Status

Stigmatization and perceived health status in patients with hidradenitis suppurativa: an observational multicenter study in Europe